Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Celestia S HiganoSabina DizdarevicJohn LogueTimothy RichardsonSaby GeorgeIgle de JongJeffrey J TomaszewskiFred SaadKurt MillerJeffrey MeltzerPer SandströmFrank VerholenBertrand TombalA Oliver SartorPublished in: Cancer (2024)
Radium-223 and chemotherapy are treatment options for metastatic prostate cancer, which increase survival but may affect production of blood cells as a side effect. We wanted to know what would happen if patients received chemotherapy after radium-223. Among the 182 men treated with radium-223 who went on to receive chemotherapy, only two men had severe side effects affecting white blood cell production (neutropenia) during chemotherapy. On average, the 182 men lived for 2 years after starting radium-223 and 1 year after starting chemotherapy. In conclusion, patients may benefit from chemotherapy after radium-223 treatment without increasing the risk of side effects.
Keyphrases
- locally advanced
- end stage renal disease
- prostate cancer
- newly diagnosed
- chronic kidney disease
- ejection fraction
- chemotherapy induced
- squamous cell carcinoma
- randomized controlled trial
- small cell lung cancer
- peritoneal dialysis
- prognostic factors
- induced apoptosis
- stem cells
- single cell
- oxidative stress
- radical prostatectomy
- cell proliferation
- middle aged
- cell therapy
- signaling pathway
- patient reported outcomes
- cell cycle arrest
- cell death
- replacement therapy
- combination therapy